key: cord-1027589-vqqmre3x
authors: Bassetti, Matteo; Giacobbe, Daniele Roberto; Bruzzi, Paolo; Barisione, Emanuela; Centanni, Stefano; Castaldo, Nadia; Corcione, Silvia; De Rosa, Francesco Giuseppe; Di Marco, Fabiano; Gori, Andrea; Gramegna, Andrea; Granata, Guido; Gratarola, Angelo; Maraolo, Alberto Enrico; Mikulska, Malgorzata; Lombardi, Andrea; Pea, Federico; Petrosillo, Nicola; Radovanovic, Dejan; Santus, Pierachille; Signori, Alessio; Sozio, Emanuela; Tagliabue, Elena; Tascini, Carlo; Vancheri, Carlo; Vena, Antonio; Viale, Pierluigi; Blasi, Francesco
title: A Response to: Letter to the Editor Regarding Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP)
date: 2021-12-10
journal: Infect Dis Ther
DOI: 10.1007/s40121-021-00564-x
sha: 808dcf74d2b06e5f3c5850386489168059806ee7
doc_id: 1027589
cord_uid: vqqmre3x

nan

Therapy (SITA) and the Italian Society of Pulmonology (SIP) on the clinical management of adult patients with coronavirus disease 2019 (COVID-19) outside intensive care units [1, 2] . In their comment, Manciulli and colleagues highlight that, while in the guidelines there is a recommendation against the use of neutralizing monoclonal antibodies in inpatients with COVID-19 (pending results of ongoing trials), the Italian Medicine Agency (AIFA) has recently allowed the use of casirivimab/imdevimab at high dosage in hospitalized seronegative patients with COVID-19 [3] . This apparent discrepancy is mostly related to the fact that the randomized trial (currently available as a nonpeer-reviewed pre-print manuscript [4] ) supporting the AIFA decision became available only very recently, after the last literature update dictating guidelines development. The possibility of novel evidence becoming available after the release of the guidelines was not unexpected. Indeed, a novel rigorous literature search supporting a predefined update of the current guidelines is about to start in November 2021, as stated in the guideline methods [1] .

Nonetheless, it is certainly true that novel evidence cannot be ignored. For this reason, pending the predefined update of the current guidelines, we invite Italian physicians to follow the most recent regulatory document, i.e., the current AIFA recommendations on the use of neutralizing monoclonal antibodies in nonhospitalized and hospitalized patients with COVID-19. However, an important point of caution is that neither the certainty of evidence nor the strength for this recommendation can be reliably defined without the proper methodology. Indeed, the formulation of the final, updated SITA and SIP recommendations on the use of neutralizing monoclonal antibodies (both in inpatients and in outpatients and both for intravenous and for other available formulations) will be provided after following the same rigorous systematic steps that were taken during the preparation of the first released document. This is necessary to guarantee the required high-quality standards for guideline development.

Funding. No funding or sponsorship was received for this study or publication of this article.

Authorship. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. Compliance with Ethics Guidelines. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/bync/4.0/.

Clinical management of adult patients with COVID-19 outside intensive care units: guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP)

Monoclonal antibodies for hospitalized patients with COVID-19 in Italy

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations